@GentiBio

GentiBio engineers regulatory T-cells in novel biosynthetic ways to address serious unmet medical needs for auto-immunity, -inflammation and allergy patients.

 Boston, MA and Seattle, WA
gentibio.com/
Joined June 2020
  • Tweets22
  • Following12
  • Followers133
6Media
Replying to @GentiBio
Learn more about the POLARIS Study: polarisstudy.com/

POLARIS Study

Newly diagnosed with Type 1 Diabetes (T1D)? The Polaris Study offers a one-time cell therapy that may slow or stop disease progression. Learn how GNTI-122 uses your own cells to rebalance your immune...

polarisstudy.com
52
Kicking off tomorrow, GentiBio joins the AAI Conference to present our latest research data and insights. For full event details, please visit the press release here: gentibio.com/press_releases/… #2026AAI #immunology #biotech #AmericanAssociationofImmunologists #Treg #CellTherapy

GentiBio to Present Advances in Engineered Regulatory T Cell Therapies at AAI 2026 - GentiBio

Cambridge, Mass., April 14, 2026 — GentiBio, a clinical stage biotechnology company advancing engineered regulatory T cell (Treg) therapies to treat autoimmune and inflammatory diseases, today...

gentibio.com
30
We are excited to be presenting at the upcoming #AAI2026 next week and connecting with colleagues across the immunology community. Our team will be sharing both seminar presentations and poster sessions highlighting our latest advances in engineered regulatory T cell therapies.
1
28
more replies
✔️ Victoria DeVault-Nelson, Associate Director, will be presenting “Comprehensive Biomarker Strategy to Monitor GNTI-122, an Engineered Regulatory T Cell Therapy in Clinical Development to Treat Type 1 Diabetes” on Saturday, April 18 (2:30 PM)
1
17
✔️Christopher Moore, Director, will be presenting “An Allogeneic CD19-Targeted Engineered Treg Approach for Treating B Cell-Mediated Autoimmune Diseases” on Saturday, April 18 (2:30 PM)
10
GentiBio has successfully dosed the first participant in our clinical trial, the POLARIS Study, for adults recently diagnosed with Type 1 Diabetes (T1D). We are incredibly proud to announce this meaningful milestone for our team and community.
2
3
1
4
668
Read the full announcement: prnewswire.com/news-releases…

GentiBio Announces First Participant Dosed in POLARIS Phase 1 Clinical Trial of GNTI-122 in...

/PRNewswire/ -- GentiBio, Inc., a clinical-stage biotechnology company pioneering engineered, antigen-specific regulatory T cell (EngTreg) therapies, today...

prnewswire.com
26
GentiBio announces preclinical data at #ESGCT showing antigen-specific engineered #Tregs suppressing pancreatic inflammation and potential utility for treatment and prevention of clinical type 1 #diabetes (#T1D)." Click here to learn more: gentibio.com/press_releases/…
1
8
We’re thrilled to announce our collaboration with global leader @bmsnews to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with IBD. Read more here: bit.ly/3zJmigp
1
3
1
7
Genti is happy to announce that Neely Mozaffarian, MD, PhD has joined as Chief Medical Officer. Please join us in welcoming Neely! prnewswire.com/news-releases…

GentiBio Appoints Neely Mozaffarian, MD, PhD as Chief Medical Officer

/PRNewswire/ -- GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for autoimmunity, autoinflammation and...

prnewswire.com
We are excited to welcome our new CFO Chuck Silberstein to the team! prnewswire.com/news-releases…

GentiBio Appoints Industry Veteran Chuck Silberstein as Chief Financial Officer

/PRNewswire/ -- GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology, today announced the...

prnewswire.com
1
2
GentiBio is thrilled to share a perspective piece on how to succeed. Our CEO, Adel Nada, discusses, in order to succeed you need to prepare for failure and the importance of learning from mistakes. Enjoy! rapport.bio/all-stories/to-s…
2
GentiBio is excited to welcome 2022 and honored to be part of this list biospace.com/article/top-lif…

Top Life Sciences Startups to Watch in 2022

BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.

biospace.com
1
3
Congratulations to our fellow @NewEnglandVC #NEVYs21 Nominees –we're so proud to be nominated alongside this group of superheroes! December 2nd we will be at the @HOBBoston for the 9th Annual NEVY Awards, and we hope you’ll join us! thenevys.com/
1
2
Proud to be working with Seattle Children's in the Treg cell therapy space! @seattlechildren pulse.seattlechildrens.org/s…
1
3
Following the successful closing of a $157 million Series A, @GentiBio will continue to develop and advance its potential functional cure for #T1D to the clinic, alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation. gentibio.com/
2
5
Load more